Neural Therapeutics Inc.
NURL
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.89% | -21.99% | -35.37% | -73.11% | -35.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.21% | -41.77% | -36.23% | -65.68% | -20.65% |
| Operating Income | 35.21% | 41.77% | 36.23% | 65.68% | 20.65% |
| Income Before Tax | 37.64% | 36.57% | -11.05% | 58.24% | 20.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.64% | 36.57% | -11.05% | 58.24% | 20.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.64% | 36.57% | -11.05% | 58.24% | 20.21% |
| EBIT | 35.21% | 41.77% | 36.23% | 65.68% | 20.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 50.00% | 50.00% | 32.35% | 74.55% | 38.46% |
| Normalized Basic EPS | 46.67% | 46.15% | 62.16% | 73.53% | 37.50% |
| EPS Diluted | 50.00% | 50.00% | 32.35% | 74.55% | 38.46% |
| Normalized Diluted EPS | 46.67% | 46.15% | 62.16% | 73.53% | 37.50% |
| Average Basic Shares Outstanding | 23.05% | 21.65% | 62.14% | 67.08% | 29.14% |
| Average Diluted Shares Outstanding | 23.05% | 21.65% | 62.14% | 67.08% | 29.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |